| Literature DB >> 35346312 |
Tomoya Takemoto1, Masayuki Baba1, Kazumasa Yokoyama2, Kohei Kitagawa1, Kazuki Nagayasu1,3, Yukio Ago4, Kaoru Seiriki1,5, Atsuko Hayata-Takano1,6, Atsushi Kasai1, Daisuke Mori7,8, Norio Ozaki7, Kazuhiro Takuma6,9, Ryota Hashimoto10, Hitoshi Hashimoto11,12,13,14,15,16, Takanobu Nakazawa17,18,19.
Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by specific social symptoms, restricted interests, stereotyped repetitive behaviors, and delayed language development. The 3q29 microdeletion (3q29del), a recurrent copy number variant, confers a high risk for ASD and schizophrenia, and serves as an important pathological model for investigating the molecular pathogenesis of a large number of neurodevelopmental and psychiatric conditions. Recently, mouse models carrying a deletion of the chromosomal region corresponding to the human 3q29 region (Df/+ mice) were generated and demonstrated neurodevelopmental and psychiatric conditions associated behavioral abnormalities, pointing to the relevance of Df/+ mice as a model for these conditions with high construct and face validity. Currently, the molecular pathogenesis of these behavioral phenotypes in Df/+ mice remains unclear. The oxytocin (OXT) system plays a central role in social behavior across species and has a potential role in ASD. In this study, to elucidate the molecular mechanisms behind impaired social behavior in Df/+ mice, we investigated the possible involvement of OXT signaling in impaired social behavior in Df/+ mice. We demonstrated that OXT administration restored the impaired social behavior in Df/+ mice. We also demonstrated that the number of OXT-positive cells in the paraventricular nucleus (PVN) was significantly lower in Df/+ mice than in wild-type (WT) littermates. Consistent with this, the level of OXT peptide in the cerebral cortex of Df/+ mice was lower than in WT littermates. Our study may provide important insights into the molecular pathophysiological basis of neurodevelopmental and psychiatric conditions, including ASD.Entities:
Keywords: 3q29 microdeletion; Autism spectrum disorder; Oxytocin; Paraventricular nucleus; Social behavior
Mesh:
Substances:
Year: 2022 PMID: 35346312 PMCID: PMC8962454 DOI: 10.1186/s13041-022-00915-w
Source DB: PubMed Journal: Mol Brain ISSN: 1756-6606 Impact factor: 4.399
Fig. 1Administration of OXT improved impaired social interaction in Df/+ mice. a Timeline for the reciprocal social interaction test with OXT treatment. The test was carried out 30 min after administration of OXT (200 µg/kg) or saline. OXT, Oxytocin. b Social interaction time in the reciprocal social interaction test (each n = 12). The time spent sniffing, following, allo-grooming, and push-crawling of test mice toward the intruder was measured as social interaction time (two-way ANOVA for genotype, F1,44 = 8.84, P = 0.0048; for treatment, F1,44 = 4.61, P = 0.037; genotype × treatment interaction, F1,44 = 3.23, P = 0.079). WT, wild-type. c (upper) Schematic illustration of the PVN (green) and (lower) representative images of OXT-Neurophysin1 immunostaining (green) and hoechst33258 staining (blue) in the PVN of adult Df/+ mice and WT littermates. Scale bar, 100 μm. d Quantification of the number of OXT-positive cells in the PVN (each n = 4 mice). e ELISA quantification of the OXT concentration in the cerebral cortex extract (each n = 8 mice). f Quantitative real-time RT-PCR analysis of the expression levels of Oxtr and Avpr1a mRNA (each n = 4 mice). Oxtr, OXT receptor; Avpr1a, vasopressin receptor 1 A. Data are represented as the mean ± SEM. Statistical significance was analyzed by a two-way ANOVA, followed by Bonferroni Dunn post hoc tests (b) and Student’s t-test (d–f). *P < 0.05, ****P < 0.0001, n,s, not significant